Indexado em
  • Abra o Portão J
  • Genamics JournalSeek
  • Chaves Acadêmicas
  • JournalTOCs
  • Bíblia de pesquisa
  • Infraestrutura Nacional de Conhecimento da China (CNKI)
  • Scimago
  • Diretório de Periódicos de Ulrich
  • Biblioteca de periódicos eletrônicos
  • RefSeek
  • Universidade de Hamdard
  • EBSCO AZ
  • OCLC- WorldCat
  • Catálogo online SWB
  • Biblioteca Virtual de Biologia (vifabio)
  • publons
  • MIAR
  • Serviços de Indexação Científica (SIS)
  • Euro Pub
  • Google Scholar
Compartilhe esta página
Folheto de jornal
Flyer image

Abstrato

Functionalization of Iron Oxide Magnetic Nanoparticles with the Multivalent Pseudopeptide N6l for Breast Tumor Targeting

Maha Sader, Pierre Couleaud, Gilles Carpentier, Maud-Emmanuelle Gilles, Noureddine Bousserrhine, Alexandre Livet, Ilaria Cascone, Damien Destouches, Aitziber L Cortajarena and José Courty

Functionalized iron oxide magnetic nanoparticles (MNP) are an innovative tool for cancer detection and treatment. In this study, a cell-surface nucleolin antagonist, N6L, was used as targeting ligand for MNP. This N6L, which exhibits antitumor activities, specifically targets bind tumor cells by binding to cell-surface nucleolin and glycosaminoglycans. N6L was covalently conjugated to dimercaptosuccinic acid coated magnetic nanoparticles (MNP-N6L). Using immunoprecipitation, gene invalidation and enzymatic degradation of glycosaminoglycans, we showed that MNP-N6L targets human breast cancer MDA-MB 231 cells through interaction with nucleolin and sulfated glycosaminoglycans. In vivo biodistribution studies were carried out in MDA-MB 231 tumor-bearing mice, using iron detection assay by spectrometric analysis and Prussian blue staining. Whereas both non-functionalized and functionalized nanoparticles were found in liver and spleen, only MNP-N6L was found in the tumor. Our findings indicate that MNP-N6L is a promising targeting system for theranostic applications in cancer detection and treatment.

Isenção de responsabilidade: Este resumo foi traduzido usando ferramentas de inteligência artificial e ainda não foi revisado ou verificado